CTIS2023-508581-15-00进行中（未招募）1 期
RandomizEd trial to DEtermine the efficacy and safety of FINErenone on morbidity and mortality among heart failure patients with left ventricular ejection fraction greater than or equal to 40% hospitalized due to an episode of acute decompensated Heart Failure (REDEFINE-HF) - 202301CPC
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 5,116
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Participant must be age =18 years of age inclusive at the time of signing the informed consent, Current hospitalization or recently discharged (within 10 days prior to screening) with the primary diagnosis of HF, Heart failure signs and symptoms at the time of hospital admission, including: a.Symptoms (at least one of the following): persistent dyspnea at rest or with minimal exertion worse than baseline, or new or worsening orthopnea b.Signs of fluid overload (at least one of the following): congestion on chest X-ray, rales on chest auscultation, clinically relevant edema (as judged by the investigator), elevated jugular venous pressure, Imaging evidence of mildly reduced or preserved EF (40% or higher) per local reading on the most recent assessment, preferably measured during current hospitalization; a historical left ventricular EF (LVEF) assessment may be used if there is no in-hospital measurement and if it was measured within 12 months prior to screening provided there was no major intervening event affecting EF such as an MI, Elevated N-terminal pro B-type natriuretic peptide (NTproBNP) =1000 pg/mL or B-type natriuretic peptide (BNP) =250 pg/mL according to the local lab for patients without atrial fibrillation (AF); or elevated NTproBNP =2000 pg/mL or BNP =500 pg/mL for patients with AF, measured during the current hospitalization or in the 72 hours prior to hospital admission. (Note: for patients treated with an angiotensin receptor neprilysin inhibitor [ARNI] in the previous 4 weeks prior to randomization, only NTproBNP values should be used.), Fulfillment of the following stabilization criteria (if randomized during hospitalization): a.Systolic blood pressure (BP) =100 mmHg and no symptoms of hypotension in the 6 hours prior to randomization b.No increase in intravenous diuretic dose for 6 hours prior to randomization c.No intravenous vasodilators, including nitrates, within the last 6 hours prior to randomization d.No intravenous inotropic drugs or mechanical circulatory support for 24 hours prior to randomization, Treatment during the index hospitalization with at least 1 intravenous dose of a loop diuretic, e.g. furosemide, torsemide, bumetanide, Women of childbearing potential can only be included in the study if a pregnancy test is negative at screening and if they agree to use adequate contraception which is consistent with local regulations regarding the methods for contraception for the duration of the study
排除标准
- •Treatment with an MRA (finerenone, spironolactone, eplerenone, canrenone, esaxerenone) within 30 days prior to randomization; treatment with MRA should not be interrupted for the purpose of enrollment into the study, Cardiomyopathy due to known acute inflammatory heart disease (e.g., acute myocarditis within 90 days prior to randomization), infiltrative diseases (e.g., amyloidosis), accumulation diseases (e.g., haemochromatosis, Fabry disease), muscular dystrophies, cardiomyopathy with reversible causes (e.g., stress cardiomyopathy), known hypertrophic obstructive cardiomyopathy, complex (according to investigator`s judgement) congenital heart disease, or known pericardial constriction, Probable alternative cause of participant’s HF symptoms that, in the opinion of the investigator, primarily accounts for patient’s symptoms; specifically, patients with severe pulmonary disease requiring home oxygen or chronic oral steroid therapy, primary pulmonary arterial hypertension at screening, Concomitant systemic therapy with potent cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors (e.g., itraconazole, ritonavir, indinavir, cobicistat, clarithromycin), or moderate CYP3A4 inducers (e.g., efavirenz, phenobarbital), or potent CYP3A4 inducers (e.g., carbamazepine, phenytoin, St John’s Wort) that cannot be discontinued 7 days prior to randomization and for the duration of the treatment period (note: a list of excluded CYP3A4 inhibitors and inducers is provided in Appendix D., Known hypersensitivity to the study intervention (active substance or excipients), Concomitant treatment with renin inhibitor, more than one angiotensin converting enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB) or ARNI, or with a potassium-sparing diuretic that cannot be stopped prior to randomization and for the duration of the treatment period, Any other condition or therapy (e.g., cardiogenic shock, clinically overt severe hepatic insufficiency, Addison’s disease, or other severe condition as per investigator’s judgment such as disease with <1 year life expectancy) which would make the participant unsuitable for this study and not allow participation for the full planned study period, Participation in another interventional clinical study or treatment with another investigational medicine or device within 30 days prior to randomization, Documented prior history of severe hyperkalemia (serum/plasma K =6.0 mmol/L and/or resulting in hospitalization or Emergency Department visit) in the setting of MRA use, eGFR <25 mL/min/1.73m² or serum/plasma potassium >5.0 mmol/L at screening, Acute MI, coronary revascularization, valve replacement/repair, or implantation of a cardiac resynchronization therapy device within 30 days prior to randomization (note: pacemakers or implantable cardioverter defibrillators without resynchronization function are allowed.), Prior heart transplant or listed for heart transplant with expectation to receive a transplant during the course of this trial (according to investigator judgement), or planned for palliative care for HF, or currently using or plan for mechanical circulatory support, e.g., left ventricular assist device, intra-aortic balloon pump, or patients on mechanical ventilation or patients with planned outpatient inotropic support, Hemodynamically significant (severe) uncorrected primary cardiac valvular disease considered by the investigator to be the primary cause of heart failure (note: secondary mitral regurgitation or tricusp
研究者
相似试验
尚未招募
3 期
A study to determine the efficacy and safety of finerenone versus placebo on morbidity and mortality among hospitalized heart failure patients (REDEFINE-HF)Heart FailureSLCTR/2024/022CPC Clinical Research
已完成
2 期
A randomized clinical trial for the efficacy and safety of local steroid injection for prevention of post-ESD esophageal stenosisEarly esophageal cancerJPRN-UMIN000006327Dept. of Gastroenterology, Keiyukai Sapporo Hospital32
进行中（未招募）
1 期
Study to evaluate the use of supplemental oxygen in patients with acute symptomatic pulmonary embolism.Acute symptomatic pulmonary embolismEUCTR2019-000266-37-ESFundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal100
进行中（未招募）
1 期
Randomized study to evaluate the efficacy of two techniques against chronic hip pain: radiofrequency over sensitive nerves of the hip, compared injection of steroids and local anestethic into the hip.Chronic Hip Pain by OsteoarthrosisEUCTR2018-000269-36-ESJORGE ORDUÑA VALLS20
尚未招募
2 期
Pumpkin (Bhopala) on mental capacity in malnourished children.CTRI/2023/02/049381Dr Sarita S Neeralakeri